

Refractory AGC patients treated with NIVO or IRI for the first time from January 2015 to June 2018 at three institutions (n = 212)

CT not performed before NIVO/IRI (n = 20)

No measurable lesions (n = 56)

No tumor refractoriness or intolerance to fluoropyrimidines and taxanes (n = 19)

Eligible patients (n = 117), NIVO (n = 32), IRI (n = 85)

Rapid group (n = 72)

NIVO (n = 19) (NL-/+ : 13/6)

IRI (n = 53) (NL-/+ : 37/16)

Slow group (n = 45)

NIVO (n = 13)

IRI (n = 32)